GSK’s Tuas facility becomes SG’s largest vaccine production site based on investment

The company invested an additional $343m for the facility’s expansion.

GSK’s facility in Tuas is now Singapore’s largest vaccine production site in terms of cumulative investment, according to Trade Minister Gan Kim Yong.

Gan, in his speech at the groundbreaking of the facility’s expansion, said investment poured into the facility has reached $850m.

GSK recently invested $343m for the facility’s expansion.

Following the expansion, the Tuas facility will begin manufacturing drug substances for GSK’s vaccines that protect against Hepatitis B.

Expansion works for the facility will commence in the third quarter of 2023 and are expected to be completed by 2025.

According to GSK, it will begin commercial production of the vaccine by 2027.

“Hepatitis B is a dangerous disease, causing serious complications in the liver. It affects 1 in 25 people in Singapore today. This vaccine will be manufactured using single-use bags, which is a novel technology within the vaccine production space,” Gan said.

|In addition, this technology would allow greater flexibility to existing manufacturing processes and enable rapid-large scale vaccine production. This advancement will further bolster Singapore’s position as a hub for innovation in this industry,” the minister added.